TEVA PHARMACEUTICAL INDUSTRIES LTD Income Statement
TEVA / Health Care|12 years of annual SEC 10-K data (FY2014-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 12 fiscal years. All figures from audited SEC 10-K filings.
TEVA PHARMACEUTICAL INDUSTRIES LTD reported $17.3B in revenue and $1.4B in net income for FY2025. Revenue has declined at a 1.3% compound annual rate over the past 10 years.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score 0.41 (distress zone, below 1.8 threshold)
- Negative profit margin: -9.9%
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $17.3B | $16.5B | $15.8B | $14.9B | $15.9B | $16.7B | $16.9B | $18.3B | $21.9B | $21.9B | $19.7B | - |
| Cost of Revenue | $8.3B | $8.5B | $8.2B | $8.0B | $8.3B | $8.9B | $9.4B | $10.0B | $11.2B | $10.3B | $8.3B | - |
| Gross Profit | $8.9B | $8.1B | $7.6B | $7.0B | $7.6B | $7.7B | $7.5B | $8.3B | $10.6B | $11.7B | $11.4B | - |
| SG&A Expense | $1.3B | $1.2B | $1.2B | $1.2B | $1.1B | $1.2B | $1.2B | $1.3B | $1.5B | $1.4B | $1.4B | - |
| R&D Expense | $1.0B | $998.0M | $953.0M | $98.0M | $967.0M | $997.0M | $1.0B | $114.0M | $175.0M | $422.0M | $35.0M | - |
| Operating Income | $2.2B | -$303.0M | $433.0M | -$2.2B | $1.7B | -$3.6B | -$443.0M | -$1.6B | -$17.5B | $2.2B | $3.4B | - |
| Interest Expense | $916.0M | $1.0B | $1.0B | $930.0M | $891.0M | $901.0M | $822.0M | $920.0M | $875.0M | $546.0M | $270.0M | - |
| Income Tax | -$180.0M | $676.0M | -$7.0M | -$643.0M | $211.0M | -$168.0M | -$278.0M | -$195.0M | -$1.9B | $521.0M | $634.0M | - |
| Net Income | $1.4B | -$1.6B | -$559.0M | -$2.4B | $417.0M | -$4.0B | -$999.0M | -$2.1B | -$16.3B | $329.0M | $1.6B | - |
| EPS (Basic) | $1.23 | -$2.20 | $0.38 | -$3.64 | -$0.91 | -$2.35 | -$16.26 | $0.07 | -$16.26 | $0.07 | $1.84 | - |
| EPS (Diluted) | $1.21 | -$2.20 | $0.38 | -$3.64 | -$0.91 | -$2.35 | -$16.26 | $0.07 | -$16.26 | $0.07 | $1.82 | - |
| Shares Outstanding | 1.2B | 1.1B | 1.1B | 1.1B | 1.1B | 1.0B | 1.0B | 961 | 1.0B | 961 | - | - |
| Gross Margin | 51.8% | 48.7% | 48.3% | 46.7% | 47.8% | 46.4% | 44.6% | 45.4% | 48.6% | 53.2% | 57.8% | - |
| Operating Margin | 12.5% | -1.8% | 2.7% | -14.7% | 10.8% | -21.4% | -2.6% | -9.0% | -80.0% | 9.8% | 17.1% | - |
| Profit Margin | 8.2% | -9.9% | -3.5% | -16.4% | 2.6% | -23.9% | -5.9% | -11.8% | - | 1.5% | 8.1% | - |